Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 18 | 2020 | 45 | 7.040 |
Why?
|
| Pain | 9 | 2020 | 25 | 2.920 |
Why?
|
| Arthralgia | 5 | 2019 | 12 | 2.800 |
Why?
|
| Osteoarthritis, Knee | 6 | 2019 | 20 | 2.280 |
Why?
|
| Animals | 30 | 2020 | 748 | 2.200 |
Why?
|
| Nociceptors | 5 | 2019 | 7 | 1.880 |
Why?
|
| Arthritis, Experimental | 5 | 2018 | 10 | 1.860 |
Why?
|
| Hyperalgesia | 5 | 2017 | 11 | 1.770 |
Why?
|
| Neurons | 3 | 2017 | 42 | 1.520 |
Why?
|
| Disease Models, Animal | 16 | 2020 | 100 | 1.490 |
Why?
|
| Cartilage, Articular | 6 | 2018 | 32 | 1.380 |
Why?
|
| Mice | 18 | 2020 | 215 | 1.350 |
Why?
|
| Humans | 20 | 2020 | 1907 | 1.180 |
Why?
|
| Nerve Growth Factor | 2 | 2017 | 4 | 1.060 |
Why?
|
| Ganglia, Spinal | 6 | 2019 | 12 | 1.020 |
Why?
|
| Chemokine CCL2 | 5 | 2018 | 7 | 0.960 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2014 | 10 | 0.960 |
Why?
|
| Peptides | 3 | 2014 | 16 | 0.910 |
Why?
|
| Knee Joint | 3 | 2019 | 16 | 0.830 |
Why?
|
| Chronic Pain | 4 | 2020 | 12 | 0.810 |
Why?
|
| Neuroimmunomodulation | 2 | 2019 | 2 | 0.790 |
Why?
|
| Nociception | 4 | 2019 | 4 | 0.780 |
Why?
|
| Male | 11 | 2020 | 1055 | 0.750 |
Why?
|
| Calcium | 3 | 2018 | 189 | 0.720 |
Why?
|
| Tissue Engineering | 2 | 2011 | 5 | 0.700 |
Why?
|
| Pain Management | 2 | 2018 | 15 | 0.690 |
Why?
|
| Immunity, Innate | 2 | 2019 | 2 | 0.670 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 6 | 0.660 |
Why?
|
| Receptors, CCR2 | 3 | 2017 | 3 | 0.650 |
Why?
|
| Synovitis | 1 | 2019 | 3 | 0.640 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 2 | 0.630 |
Why?
|
| Cytokines | 3 | 2019 | 18 | 0.630 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 7 | 0.630 |
Why?
|
| Aggrecans | 2 | 2018 | 4 | 0.590 |
Why?
|
| ADAM Proteins | 2 | 2015 | 2 | 0.590 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 1 | 0.570 |
Why?
|
| Cannabis | 1 | 2017 | 1 | 0.550 |
Why?
|
| Phytotherapy | 1 | 2017 | 1 | 0.550 |
Why?
|
| Cannabinoids | 1 | 2017 | 2 | 0.550 |
Why?
|
| Clozapine | 1 | 2017 | 1 | 0.540 |
Why?
|
| Neural Inhibition | 1 | 2017 | 3 | 0.540 |
Why?
|
| Behavior, Animal | 1 | 2017 | 8 | 0.530 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 5 | 0.520 |
Why?
|
| Mice, Inbred C57BL | 8 | 2019 | 54 | 0.510 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 1 | 0.480 |
Why?
|
| Stifle | 1 | 2015 | 2 | 0.480 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 6 | 0.470 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 5 | 0.450 |
Why?
|
| Tissue Scaffolds | 2 | 2011 | 7 | 0.440 |
Why?
|
| Orthopedic Procedures | 1 | 2014 | 3 | 0.440 |
Why?
|
| Joints | 1 | 2014 | 9 | 0.440 |
Why?
|
| Mice, Knockout | 5 | 2018 | 40 | 0.420 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 1 | 0.410 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 1 | 0.410 |
Why?
|
| Drug Carriers | 1 | 2011 | 1 | 0.360 |
Why?
|
| Blood Coagulation | 3 | 2006 | 4 | 0.360 |
Why?
|
| Heparin | 2 | 2010 | 4 | 0.360 |
Why?
|
| Female | 5 | 2020 | 984 | 0.350 |
Why?
|
| Chondroitin Sulfates | 1 | 2010 | 1 | 0.340 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 2 | 0.340 |
Why?
|
| Chondrogenesis | 1 | 2010 | 10 | 0.340 |
Why?
|
| Cells, Cultured | 4 | 2015 | 88 | 0.320 |
Why?
|
| Menisci, Tibial | 3 | 2017 | 4 | 0.310 |
Why?
|
| Plasma | 2 | 2006 | 5 | 0.300 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 7 | 0.270 |
Why?
|
| ADAMTS5 Protein | 2 | 2018 | 2 | 0.260 |
Why?
|
| Signal Transduction | 2 | 2019 | 73 | 0.250 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 18 | 0.240 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 7 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 22 | 0.240 |
Why?
|
| Models, Theoretical | 3 | 2020 | 16 | 0.230 |
Why?
|
| Synovial Membrane | 2 | 2017 | 6 | 0.220 |
Why?
|
| Cattle | 3 | 2014 | 14 | 0.200 |
Why?
|
| Hydrogels | 3 | 2014 | 4 | 0.200 |
Why?
|
| Chondrocytes | 2 | 2014 | 16 | 0.200 |
Why?
|
| Analgesics | 2 | 2020 | 8 | 0.200 |
Why?
|
| Radiography | 2 | 2014 | 35 | 0.190 |
Why?
|
| Biomarkers | 2 | 2019 | 56 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 25 | 0.170 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 17 | 0.170 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2020 | 1 | 0.170 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 1 | 0.160 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 1 | 0.160 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 1 | 0.160 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 2 | 0.160 |
Why?
|
| Alarmins | 1 | 2019 | 1 | 0.160 |
Why?
|
| Disease Progression | 1 | 2019 | 43 | 0.160 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 16 | 0.150 |
Why?
|
| Rats | 2 | 2018 | 159 | 0.150 |
Why?
|
| Random Allocation | 2 | 2016 | 12 | 0.140 |
Why?
|
| ADAMTS4 Protein | 1 | 2018 | 1 | 0.140 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 1 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 4 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2018 | 27 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 95 | 0.140 |
Why?
|
| Central Nervous System Sensitization | 1 | 2017 | 1 | 0.140 |
Why?
|
| Albuminuria | 1 | 2017 | 1 | 0.140 |
Why?
|
| TRPC Cation Channels | 1 | 2017 | 1 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cannabidiol | 1 | 2017 | 1 | 0.140 |
Why?
|
| Dronabinol | 1 | 2017 | 1 | 0.140 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 4 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 2 | 0.130 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 2 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 7 | 0.130 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 43 | 0.130 |
Why?
|
| Catalysis | 3 | 2013 | 4 | 0.130 |
Why?
|
| Chemokines, CC | 1 | 2017 | 1 | 0.130 |
Why?
|
| Drug Design | 2 | 2014 | 2 | 0.130 |
Why?
|
| Osteonecrosis | 1 | 2017 | 1 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 4 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 2 | 0.130 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 2 | 2014 | 2 | 0.130 |
Why?
|
| Chemokine CX3CL1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Microglia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Calgranulin A | 1 | 2015 | 1 | 0.120 |
Why?
|
| alpha-Macroglobulins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 1 | 0.120 |
Why?
|
| Adsorption | 2 | 2014 | 2 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 3 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2015 | 16 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 4 | 0.110 |
Why?
|
| Horses | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 2 | 0.110 |
Why?
|
| Arthroscopy | 1 | 2014 | 4 | 0.110 |
Why?
|
| Dogs | 1 | 2014 | 58 | 0.110 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 53 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 59 | 0.110 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 3 | 0.100 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 3 | 0.100 |
Why?
|
| Macrophages | 1 | 2012 | 8 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2012 | 38 | 0.100 |
Why?
|
| Streptavidin | 1 | 2011 | 1 | 0.090 |
Why?
|
| Biotinylation | 1 | 2011 | 1 | 0.090 |
Why?
|
| Fluorometry | 1 | 2011 | 2 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 2 | 0.090 |
Why?
|
| Solubility | 1 | 2011 | 2 | 0.090 |
Why?
|
| Glycosaminoglycans | 1 | 2011 | 4 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2011 | 20 | 0.090 |
Why?
|
| DNA | 1 | 2011 | 21 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 11 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2011 | 9 | 0.090 |
Why?
|
| Kinetics | 1 | 2011 | 59 | 0.090 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Polysaccharide-Lyases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 2 | 0.090 |
Why?
|
| Injections, Intra-Articular | 1 | 2010 | 3 | 0.090 |
Why?
|
| Models, Animal | 1 | 2010 | 25 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 5 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 6 | 0.080 |
Why?
|
| Rabbits | 1 | 2010 | 52 | 0.080 |
Why?
|
| Surface Properties | 2 | 2006 | 17 | 0.080 |
Why?
|
| Models, Biological | 2 | 2005 | 99 | 0.070 |
Why?
|
| Protein Engineering | 1 | 2008 | 3 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 64 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 12 | 0.070 |
Why?
|
| Silanes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 2 | 0.060 |
Why?
|
| Factor XII | 1 | 2005 | 1 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 2 | 0.060 |
Why?
|
| Coagulants | 1 | 2005 | 3 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 11 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 48 | 0.050 |
Why?
|
| Collagen Type V | 1 | 2020 | 1 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 11 | 0.040 |
Why?
|
| Neurons, Afferent | 1 | 2018 | 1 | 0.040 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2017 | 1 | 0.030 |
Why?
|
| Podocytes | 1 | 2017 | 1 | 0.030 |
Why?
|
| Piperidines | 1 | 2017 | 4 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 8 | 0.030 |
Why?
|
| Indoles | 1 | 2017 | 7 | 0.030 |
Why?
|
| Brain | 1 | 2017 | 92 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 12 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 27 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 21 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aged | 1 | 2017 | 418 | 0.030 |
Why?
|
| Middle Aged | 1 | 2017 | 494 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 14 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 6 | 0.030 |
Why?
|
| Adult | 1 | 2017 | 554 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 10 | 0.030 |
Why?
|
| Epitopes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 11 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2014 | 19 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 1 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2008 | 5 | 0.020 |
Why?
|
| Binding Sites | 1 | 2008 | 12 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 21 | 0.020 |
Why?
|
| Factor XIIa | 1 | 2005 | 1 | 0.010 |
Why?
|
| Titrimetry | 1 | 2005 | 3 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 17 | 0.010 |
Why?
|
| Thrombin | 1 | 2005 | 4 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 3 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 20 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 2005 | 6 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 143 | 0.010 |
Why?
|